Correction to: Ritlecitinib: First Approval.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Works matching IS 00126667 AND DT 2023 AND VI 83 AND IP 15
Results: 10
1
2
Avacincaptad Pegol: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 15, p. 1447, doi. 10.1007/s40265-023-01948-8
- By:
- Publication type:
- Article
3
Correction to: Birch Bark Extract: A Review in Epidermolysis Bullosa.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
4
Befotertinib: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 15, p. 1433, doi. 10.1007/s40265-023-01946-w
- By:
- Publication type:
- Article
5
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
- Published in:
- Drugs, 2023, v. 83, n. 15, p. 1409, doi. 10.1007/s40265-023-01936-y
- By:
- Publication type:
- Article
6
Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification.
- Published in:
- Drugs, 2023, v. 83, n. 15, p. 1387, doi. 10.1007/s40265-023-01938-w
- By:
- Publication type:
- Article
7
Talquetamab: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 15, p. 1439, doi. 10.1007/s40265-023-01945-x
- By:
- Publication type:
- Article
8
Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.
- Published in:
- Drugs, 2023, v. 83, n. 15, p. 1425, doi. 10.1007/s40265-023-01943-z
- By:
- Publication type:
- Article
9
Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?
- Published in:
- Drugs, 2023, v. 83, n. 15, p. 1351, doi. 10.1007/s40265-023-01942-0
- By:
- Publication type:
- Article
10
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options.
- Published in:
- Drugs, 2023, v. 83, n. 15, p. 1365, doi. 10.1007/s40265-023-01934-0
- By:
- Publication type:
- Article